EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer-Reference-Cited by-同舟云学术

EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer

Published:2017-07-26 Issue:11 Volume:6 Page:e1356145
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Dong Zhong-Yi¹²,Zhang Jia-Tao¹,Liu Si-Yang¹,Su Jian¹,Zhang Chao¹^ORCID,Xie Zhi¹,Zhou Qing¹,Tu Hai-Yan¹,Xu Chong-Rui¹,Yan Li-Xu³,Li Yu-Fa³,Zhong Wen-Zhao¹,Wu Yi-Long¹

Affiliation:

1. Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China

2. Southern Medical University, Guangzhou, China

3. Department of Pathology and Laboratory Medicine, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2017.1356145

Reference37 articles.

1. EGFRMutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

2. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

3. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation

4. KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma

5. Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients

Cited by 321 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination of radiotherapy and PD-L1 blockade induces abscopal responses in EGFR-mutated lung cancer through activating CD8+ T cells;Translational Oncology;2024-10

2. Immunotherapy in EGFR-Mutant Non–Small Cell Lung Cancer: End of the Road or the First Chapter?;Journal of Clinical Oncology;2024-08-26

3. Dissecting heterogeneity of tumor microenvironment in colorectal cancer using high-resolution single-cell atlas;2024-08-26

4. Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR–Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer;Journal of Clinical Oncology;2024-08-22

5. Efficacy analysis of immunotherapy‑based combinations for patients with EGFR‑mutant advanced non‑small cell lung cancer after TKI failure;Oncology Letters;2024-08-20